The clinical-stage biotech company is based in Sacramento, and is putting its drug candidate through medical trials.

IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programs "Molecular ...

A new study suggests Donald Trump’s love of golf and Florida residence may be putting him at risk of an unexpected health ...

This article outlines how modern toxins and lifestyle stressors overburden the liver, leading to symptoms many people ...

The 4:3 intermittent fasting diet alternates fasting and eating regularly every other day. Here's how it works, weight loss, ...

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

After the wildfires in California last year, she had two-and-a-half liters of plasma removed from her body in an effort to filter out the toxins her body had accumulated from the low air quality (“You ...

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a ...

U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting con ...

Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell ...

A Type D meeting was held with the FDA in March 2025 to discuss the potential regulatory path for OPGx-LCA5, including the ...

Health Secretary Robert F. Kennedy Jr. is standing firm on the sweeping cuts to the Department of Health and Human Services, ...